We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Platform for Cloning and Modifying DNA

By Biotechdaily staff writers
Posted on 28 Jun 2002
A DNA engineering platform employs new technology called lambda mediated cloning, or Red/ET Recombination, which allows for cloning and precise modification of DNA molecules, regardless of size and composition.

The technology allows researchers to quickly and efficiently build DNA engineering portfolios, often reducing waiting time for results from around three months to only two weeks or less. More...
Modifications such as point mutations, sequence insertions, and deletions can be carried out at any chosen position on a target DNA molecule. The technology was originally developed at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, by the cofounders of Gene Bridges GmbH (Dresden, Germany), which is now commercializing the technology. Red/ET Recombination is available through a licensing arrangement or via a service contract, whereby researchers can send to Gene Bridges the DNA materials they would like to have modified.

"In terms of DNA cloning and subcloning, Red/ET Recombination is a far superior alternative to traditional in vitro DNA amplification strategies, which rely on inconvenient restriction sites and are prone to mutations derived from PCR amplification,” said Prof. Francis Stewart, chairman of Gene Bridges.


Related Links:
Gene Bridges

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.